We treated four patients with acromegaly for 8 to 24 weeks with SMS 201-995, the long-acting somatostatin analogue, in dosages of 100 to 300 micrograms a day given subcutaneously. A rapid amelioration of the clinical signs and symptoms and near normalization of laboratory test results occurred in all patients. Mean plasma growth hormone concentrations (+/- S.E.M.), as measured over 24 hours, fell from an initial value of 57 +/- 18 micrograms per liter to 7.5 +/- 2 micrograms per liter at the end of the investigational period. Likewise, levels of plasma somatomedin-C, which were originally elevated in all patients, dropped to the normal or nearly normal range. The suppression of insulin secretion and the resulting hyperglycemia that were observed at the beginning of treatment became less marked as therapy progressed. There was evidence of slight tumor shrinkage in three of the subjects. No side effects were recorded throughout the treatment period. These preliminary results suggest that SMS 201-995 represents an additional option for the management of acromegaly, especially in patients who do not benefit sufficiently from surgery or radiotherapy and do not respond well to treatment with dopaminergic drugs.
This article has been cited by other articles:
Colao, A., Auriemma, R. S., Savastano, S., Galdiero, M., Grasso, L. F. S., Lombardi, G., Pivonello, R.
(2009). Glucose Tolerance and Somatostatin Analog Treatment in Acromegaly: A 12-Month Study. J. Clin. Endocrinol. Metab.
94: 2907-2914
[Abstract][Full Text]
Mazziotti, G., Floriani, I., Bonadonna, S., Torri, V., Chanson, P., Giustina, A.
(2009). Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies. J. Clin. Endocrinol. Metab.
94: 1500-1508
[Abstract][Full Text]
Colao, A., Auriemma, R. S., Galdiero, M., Cappabianca, P., Cavallo, L. M., Esposito, F., Grasso, L. F. S., Lombardi, G., Pivonello, R.
(2009). Impact of Somatostatin Analogs Versus Surgery on Glucose Metabolism in Acromegaly: Results of a 5-Year Observational, Open, Prospective Study. J. Clin. Endocrinol. Metab.
94: 528-537
[Abstract][Full Text]
Murray, R. D., Melmed, S.
(2008). A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly. J. Clin. Endocrinol. Metab.
93: 2957-2968
[Abstract][Full Text]
van der Hoek, J., Lamberts, S. W J, Hofland, L. J
(2007). Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. Eur J Endocrinol
156: S45-S51
[Abstract][Full Text]
Colao, A., Ferone, D., Marzullo, P., Lombardi, G.
(2004). Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. Endocr. Rev.
25: 102-152
[Abstract][Full Text]
van der Hoek, J., de Herder, W. W., Feelders, R. A., van der Lely, A.-J., Uitterlinden, P., Boerlin, V., Bruns, C., Poon, K. W., Lewis, I., Weckbecker, G., Krahnke, T., Hofland, L. J., Lamberts, S. W.
(2004). A Single-Dose Comparison of the Acute Effects between the New Somatostatin Analog SOM230 and Octreotide in Acromegalic Patients. J. Clin. Endocrinol. Metab.
89: 638-645
[Abstract][Full Text]
Kopchick, J. J., Parkinson, C., Stevens, E. C., Trainer, P. J.
(2002). Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly. Endocr. Rev.
23: 623-646
[Abstract][Full Text]
Losa, M., Ciccarelli, E., Mortini, P., Barzaghi, R., Gaia, D., Faccani, G., Papotti, M., Mangili, F., Terreni, M. R., Camanni, F., Giovanelli, M.
(2001). Effects of Octreotide Treatment on the Proliferation and Apoptotic Index of GH-Secreting Pituitary Adenomas. J. Clin. Endocrinol. Metab.
86: 5194-5200
[Abstract][Full Text]
Danila, D. C., Haidar, J. N. S., Zhang, X., Katznelson, L., Culler, M. D., Klibanski, A.
(2001). Somatostatin Receptor-Specific Analogs: Effects on Cell Proliferation and Growth Hormone Secretion in Human Somatotroph Tumors. J. Clin. Endocrinol. Metab.
86: 2976-2981
[Abstract][Full Text]
Afargan, M., Janson, E. T., Gelerman, G., Rosenfeld, R., Ziv, O., Karpov, O., Wolf, A., Bracha, M., Shohat, D., Liapakis, G., Gilon, C., Hoffman, A., Stephensky, D., Oberg, K.
(2001). Novel Long-Acting Somatostatin Analog with Endocrine Selectivity: Potent Suppression of Growth Hormone But Not of Insulin. Endocrinology
142: 477-486
[Abstract][Full Text]
Kato, Y., Akhteruzzaman, S., Hisaka, A., Sugiyama, Y.
(1999). Hepatobiliary Transport Governs Overall Elimination of Peptidic Endothelin Antagonists in Rats. J. Pharmacol. Exp. Ther.
288: 568-574
[Abstract][Full Text]
Chan, N N, Isaacs, A J
(1999). Lack of response to octreotide in Cushing's syndrome due to metastatic adrenocortical carcinoma. Postgrad. Med. J.
75: 96-98
[Abstract][Full Text]
Colao, A., Marzullo, P., Vallone, G., Marinò, V., Annecchino, M., Ferone, D., de Brasi, D., Scarpa, R., Oriente, P., Lombardi, G.
(1998). Reversibility of Joint Thickening in Acromegalic Patients: An Ultrasonography Study. J. Clin. Endocrinol. Metab.
83: 2121-2125
[Abstract][Full Text]
Yang, I., Park, S., Woo, J., Kim, S., Kim, J., Kim, Y., Choi, Y.
(1997). Growth Hormone Response to the Hypothalamic Somatostatinergic Activity in Acromegalic Patients. J. Clin. Endocrinol. Metab.
82: 2492-2496
[Abstract][Full Text]
Yamada, T., Niinuma, K., Lemaire, M., Terasaki, T., Sugiyama, Y.
(1997). CARRIER-MEDIATED HEPATIC UPTAKE OF THE CATIONIC CYCLOPEPTIDE, OCTREOTIDE, IN RATS. Comparison between In Vivo and In Vitro. Drug Metab. Dispos.
25: 536-543
[Abstract][Full Text]
Caron, P., Morange-Ramos, I., Cogne, M., Jaquet, P.
(1997). Three Year Follow-Up of Acromegalic Patients Treated with Intramuscular Slow-Release Lanreotide. J. Clin. Endocrinol. Metab.
82: 18-22
[Abstract][Full Text]
Lamberts, S. W.J., van der Lely, A.-J., de Herder, W. W., Hofland, L. J.
(1996). Octreotide. NEJM
334: 246-254
[Full Text]
Ezzat, S., Snyder, P. J., Young, W. F., Boyajy, L. D., Newman, C., Klibanski, A., Molitch, M. E., Boyd, A. E., Sheeler, L., Cook, D. M., Malarkey, W. B., Jackson, I., Vance, M. L., Thorner, M. O., Barkan, A., Frohman, L. A, Melmed, S.
(1992). Octreotide Treatment of Acromegaly: A Randomized, Multicenter Study. ANN INTERN MED
117: 711-718
[Abstract]
Lim, M. J., Barkan, A. L., Buda, A. J.
(1992). Rapid Reduction of Left Ventricular Hypertrophy in Acromegaly after Suppression of Growth Hormone Hypersecretion. ANN INTERN MED
117: 719-726
[Abstract]
Vance, M. L., Harris, A. G.
(1991). Long-term Treatment of 189 Acromegalic Patients With the Somatostatin Analog Octreotide: Results of the International Multicenter Acromegaly Study Group. Arch Intern Med
151: 1573-1578
[Abstract]
Chanson, P., Timsit, J., Masquet, C., Warnet, A., Guillausseau, P.-J., Birman, P., Harris, A. G., Lubetzki, J.
(1990). Cardiovascular Effects of the Somatostatin Analog Octreotide in Acromegaly. ANN INTERN MED
113: 921-925
[Abstract]
Ho, K. Y., Weissberger, A. J., Marbach, P., Lazarus, L.
(1990). Therapeutic Efficacy of the Somatostatin Analog SMS 201-995 (Octreotide) in Acromegaly: Effects of Dose and Frequency and Long-Term Safety. ANN INTERN MED
112: 173-181
[Abstract]
Barakat, S., Melmed, S.
(1989). Reversible Shrinkage of a Growth Hormone-Secreting Pituitary Adenoma by a Long-Acting Somatostatin Analogue, Octreotide. Arch Intern Med
149: 1443-1445
[Abstract]
Gorden, P., Comi, R. J., Maton, P. N., Go, V. L. W.
(1989). Somatostatin and Somatostatin Analogue (SMS 201-995) in Treatment of Hormone-Secreting Tumors of the Pituitary and Gastrointestinal Tract and Non-Neoplastic Diseases of the Gut. ANN INTERN MED
110: 35-50
[Abstract]
BARNARD, L. B., WILLIAM G., G., LAMBERTON, P., O'DORISIO, T. M., JACKSON, I. M. D.
(1986). Treatment of Resistant Acromegaly with a Long-Acting Somatostatin Analogue (SMS 201-995). ANN INTERN MED
105: 856-861
[Abstract]
Previous
